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Introduction 
In Japan, incidence of cognitive disorders has been increasing and clinical studies on 
dementia have been very important. Functional neuroimaging of early Alzheimer's disease 
(AD) using PET and [18F]fluorodeoxyglucose ([18F]FDG) has demonstrated that a decrease 
in the cerebral metabolic rate of glucose (CMRglc) often starts in the posterior cingulate 
gyrus and further propagates to the temporo-parietal regions and others.  But the regional 
metabolic reduction is not so obvious and widespread in the early stage of disease course 
including mild cognitive impairment (MCI)1).  Neuronal damage is associated with high 
deposition of amyloid β (Aβ) protein in the brain, and massive neuronal loss is often 
preceded by high Aβ deposition.  An early diagnosis of mild AD can be established if we use 
a proper tracer that specifically-binds to Aβ proteins in the brain of patients. 
 “Aβ imaging” using PET has been recognized as one of the most important 
methods for diagnosing early AD partly because of excellent sensitivity of PET technique2). 
A large number of candidate compounds have already been tested in basic studies and 
several compounds were selected for clinical studies3). Clinical PET studies have been 
conducted using several probes such as [18F]FDDNP4), [11C]SB-135) and [11C]Pittsburgh 
compound-B ([11C]PIB) 6, among which [11C]PIB has been used the most widely in the 
world6-8).  Many studies have clearly demonstrated that the [11C]PIB binds to Aβ fibrils, 
enabling noninvasive assessment of Aβ deposition in the brain of AD patients as a 
biomarker for AD6).  
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Considering the importance of Aβ imaging, our group also developed a novel PET 
tracer, 2-(2-[2-demethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole 
(BF-227), probably the first original compound used for human study in Japan9).  Our 
clinical study has demonstrated that this compound is able to finely detect Aβ deposition 
primarily in the posterior association area of AD patients and accumulation in the frontal 
area is not prominent . In contrast to [11C]PIB, interestingly, [11C]BF-227 seems to be able 
to detect senile plaques containing dense amyloid fibrils preferentially, providing unique 
and specific information regarding the Aβ pathology in AD patients9).  In addition, we 
compared the [11C]BF-227 PET to structural MRI and FDG PET for diagnosing and 
tracking the severity of AD, to demonstrate that [11C]BF-227 PET was more sensitive than 
MRI in diagnosing AD and detecting converters from MCI to AD10).  These studies have 
indicated that [11C]BF-227 PET is a useful method for early diagnosis of AD and for 
predicting potential converters from MCI to AD10,11).  
Though these above PET studies have succeeded in demonstrating [11C]BF-227 is 
a useful tracer, they have used standardized uptake values (SUV) as a tool for clinical 
evaluation, that is a semi-quantitative measure, simply corrected for the injected dose and 
the body size of the subject.  Precise quantitative examination may give a better rational to 
the use of such a simple method as a clinical tool, as experienced with [11C]PIB7,8).  
However, we have not conducted the precise examination of pharmacokinetics of 
[11C]BF-227 in the human brain using arterial sampling data.  In this paper, quantification 
methods for Aβ imaging with PET is briefly overviewed and preliminary results of 
[11C]BF-227 PET are discussed.  
 
Matrials and Methods 
For the present study, 6 AD patients (mean age: 73 years old) and 6 healthy 
volunteers (mean age: 61 years old) were recruited.  PET scan was initiated simultaneously 
to the [11C]BF-227 injection, in order to obtain dynamic data of 23 time frames.  Serial 
arterial blood sampling was also done. Metabolite fraction was also examined using the 
blood data at 5, 15, 30 and 60 min post-injection and the fraction data were used for 
correction of input functions.  The dynamic PET data were coregistered to the individual 
MRI T1 images for defining regions of interest (ROIs) in the cortex and subcortical deep 
nuclei (Figs. 1a and 1b).  This study was approved by the ethics committee of Tohoku 
University Graduate School of Medicine, and informed consent was obtained from each 
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subject.  In analysis, distribution volume (DV) and binding potential (BP) values of 
[11C]BF-227 were estimated based on full kinetic compartmental model based on the 
1-tisssue (1TM) and 2-tissues models (2TM) (Fig. 1d).  Graphical analysis methods were 
also applied using 2 types of Logan graphical analysis methods; one using the time-activity 
curve (TAC) of arterial plasma data as an input function for analysis (LGA)12) and the other 
using the TAC of the reference brain tissue (cerebellum) (LGAR)13) (Fig. 1c).  PMOD 
software ver. 3.0 (PMOD Technologies, Zurich, Switzerland) was used for calculation.  The 
results of compartmental model analysis and graphical analysis were compared to the SUV 
and the SUV ratios to the cerebellar SUV (cerebellar SUVR).  Correlations among these 
different methods were examined one another 14). 
 
Results 
No clear difference was observed in the plasma TAC between AD patients and 
controls. But, clear difference was observed in the tissue TAC between AD patients and 
controls.  [11C]BF-227 accumulation was significantly higher in the cerebral cortex than in 
the cerebellum of AD patients, while there was no difference in Control.  In the analysis 
results, it turned out that 2TM better described the pharmacokinetics of [11C]BF-227 than 
1TM (Fig. 2).  The DV and BP values of [11C]BF-227 showed significantly higher in AD 
patients than in controls, and the most prominent difference was observed in the 
temporo-occipital and lateral temporal regions14).  Next, both the DV values correlated well 
between the two methods such as 2TM and LGA (r2 >0.95 in all regions).  In addition, 
results of LGA and LGAR also correlated well.  The LGA values also correlated well to the 
SUV and SUVR (r2 >0.94 in all regions) 14). 
 
Discussion 
Nowadays, Aβ imaging using PET has been recognized as one of the most 
effective methods for diagnosing early AD and for predicting potential converters from 
MCI to AD2,6).  Several promisin5) and [11C]PIB6), among which [11C]PIB has been regarded 
as the most successful Aβ imaging probe.  Though an initial study was done without 
arterial blood sampling and mainly used SUV for clinical evaluation6, the results of 
quantitative study was reported in the details8).  
Initial studies using [11C]BF-227 have been conducted in a similar manner.  Kudo 
and colleagues reported that this compound was able to finely detect Aβ deposition 
 167 
primarily in the posterior association area of AD patients, suggesting that [11C]BF-227 
might be able to detect senile plaques containing dense amyloid fibrils preferentially, in 
contrast to [11C]PIB, providing unique and specific information regarding the Aβ pathology 
in AD patients9).  In addition, we performed the comparative study between [11C]BF-227 
PET and structural MRI for the diagnosis and tracking the severity of AD.  The results 
demonstrated that PET and [11C]BF-227 was more sensitive than the result of MRI 
voxel-based morphometry (VBM)10).  Another study demonstrated that [11C]BF-227 was 
more sensitive than FDG PET in diagnosing AD and detecting converters from MCI to 
AD11).  Thus, these studies may suggest that Aβ PET imaging is more sensitive than the 
detection of hippocampal atrophy using MRI and the glucose metabolic reduction measured 
by PET, in diagnosing early AD and predicting potential converters from MCI to AD.  
The pharmacokinetics of [11C]PIB has been thoroughly examined using various 
quantification methods such as full kinetic analysis and graphical analysis7,8).  In their full 
kinetic analyses, commonly-used compartmental models are the 3 compartmental model 
(2-tissue compartmental model: 2TM), where one blood compartment and 2 tissue 
compartments with specific and non-specific binding are assumed, and the 2 compartmental 
model (1-tissue compartmental model: 1TM), where one tissue compartment represents 
both the specific and non-specific binding7,8).  When the tracer penetrates the blood-brain 
barrier (BBB) into the tissue compartment very rapidly, 1-tissue compartmental model 
might better describe the kinetics of the tracer. In the analysis of [11C]PIB, it seems that the 
2TM better described the kinetics of tracer binding to the Aβ in the human brain7,8).  Price 
and colleagues reported that Logan graphical analysis (LGA) were more useful and robust 
than the result of analysis using 2TM.  However, interesting point is that the cerebellum 
itself, the reference regions that is thought to be free of mature Aβ plaques, was better 
described based on the 2TM8).  Though many [11C]PIB papers employ the use of DVR 
values for clinical evaluation, the use of BP was also proposed in the paper by Mintun and 
colleagues7).  
As for [11C]BF-227, the results of compartmental analysis indicated that 2TM 
showed better fitting than 1TM likely in the case of [11C]PIB8).  Linearization by LGA 
method was also successful, likely in the case of [11C]PIB.  Significant correlation between 
the DV values calculated by 2TM and LGA (and LGAR, as well) may suggest that Logan 
methods are fully applicable to the quantification of [11C]BF-227.  Significant correlation of 
the results of Logan methods to the SUV (and SUVR) may suggest that clinical evaluation 
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of Aβ deposition using [11C]BF-227 PET can be done by using LGA (and LGAR, as well) 
and SUV and SUVR.  These results can reconfirm the reliability of the results of our recent 
studies9-11).  
In summary, it is demonstrated that [11C]BF-227 is a promising tracer for Aβ 
imaging; diagnosing AD patients and detecting potential converters from MCI to AD.  In 
addition to the study on AD diagnosis, recently, further clinical applications of [11C]BF-227 
PET have been tried and successful, for instance, to visualize pathological prion protein in 
prion diseases15)  and to imaging of a-synuclein deposition in multiple system atrophy16).  
For future prospects, in order to obtain more accurate examination, however, 
correction for partial volume effect should be considered.  This partial volume correction 
(PVC) is important because of the following 2 reasons; one due to local atrophy in AD 
patients, and the other reason due to relatively high accumulation of [11C]BF-227 in the 
white matter, as experienced in the analysis of [11C]PIB PET 8).  
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Figure 1.  Regions of interest (ROIs) defined in the cerebral cortex and subcortical deep nuclei in the MRI (a) 
and the co-registered PET image taken from a healthy volunteer subject (b); result of linearization using 
Logan graphical analysis (c); and time activity curves in plasma and brain tissue for compartmental model 
analysis (d) are demonstrated.  
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Figure 2.  Results of fitting for the time activity curve in the temporoparietal cortex of an Alzheimer’s disease 
patient based on 1-tissue (LEFT) and 2-tissue compartmental models (RIGHT).  2-tissue model gives better 
fitting result. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
